



**The CytoTools AG has gained a new anchor investor and increased its share in the DermaTools Biotech GmbH, thus creating the first prerequisites for the planned European phase III trials.**

- The CytoTools AG received nearly 1.5 million EUR of fresh capital
- A new institutional investor with a medium to long term investment strategy
- DermaTools implements capital increase and receives about 1 million EUR of fresh capital
- The CytoTools AG thus increases its share to over 60%

Darmstadt, 15<sup>th</sup> November 2018 – Within the scope of a cash capital increase (by 212,000.00 EUR to 2,332,252.00 EUR), decided last week, the CytoTools AG (WKN: A0KFRJ; ISIN: DE000A0KFRJ1) has gained a further anchor investor who is convinced by the potential of our enterprise. This German institutional investor, who, among other projects, also invests in further domestic issuers in the biotechnology field, wishes to accompany CytoTools in the medium to long term. The Managing Board welcomes this commitment because it gives the company further financial backing for the planned investments in the coming year. Additionally, with a long planned capital increase at DermaTools Biotech GmbH, the CytoTools has increased its share to over 60%.

CytoTools has various active substance and therapy approaches at its disposal, however currently, it is concentrating on the development of DermaPro® which enables the successful treatment of chronic wounds, in particular the diabetic foot syndrome – a problem worldwide.

After, as we reported earlier, the expected verification was unsuccessful for the decisive European clinical study of DermaPro® three years ago, which the company demonstrated was due to an error made by the manufacturer in the active substance concentration, then, on behalf of DermaTools, an action for damages was brought against this contract manufacturer. Last week, within the scope of these proceedings, there was a further court hearing where a new judge (his predecessor had gone into retirement) proposed an out-of-court settlement to the parties. The proceedings will be continued at the beginning of 2019 and probably a first decision regarding the expected considerable sum of damages will be made in 2019.



### **Market approval in India: Stability recognized, all prerequisites fulfilled, final release by the authorities still pending.**

After, in March 2017, Centaur, CytoTools' license partner, was granted approval for DermaPro® in India, on the basis of the results of a phase III trial, and subject to the condition of local active substance production, subsequently, all the necessary steps were taken, after the creation of the necessary capacity, in order to obtain the release by the authorities of this production at Centaur, the Indian partner. Then finally, also samples of the manufactured active substance solutions were requested. Now that these samples have been submitted, everything has been done to satisfy the requirements of the authorities. CytoTools and Centaur are now waiting for the final release in order, at last, to commence production for the sales launch of the drug in India under the name Woxheal. In the coming weeks, the Management Board, will personally make inquiries on site in Mumbai and New Delhi regarding the status of the proceedings. They will take all the required steps so that the production can begin promptly and smoothly. India is an important market with worldwide the largest number of diabetes patients and thus also the commonly occurring diabetic foot syndrome.

### **The European dosage trial is continuing as planned, in 2019, phase III trials are to follow**

The European phase II dosage trial for DermaPro® is running on time. Patient recruiting already started mid year, after in July, an independent testing laboratory confirmed that the trial medication manufactured in India by our partner Centaur corresponded with the specifications for Europe. CytoTools expects to be able to report the first results of the intermediate evaluation, as planned, in the first quarter of 2019. If there is, as expected, a positive course of events in the clinical phase, then for the coming year two further clinical phase III trials with DermaPro® in Europe will follow. The financial means generated by the capital increase are already funding the first preparatory measures for this important step in the market development in Europe.

*This press release contains specific future oriented statements. These reflect the opinion of CytoTools on the date of this release. The actual results achieved by CytoTools could substantially deviate from the future-oriented statements made. CytoTools is not obligated to update these future-oriented statements.*



### **About CytoTools**

CytoTools AG is a German biotechnology company focused on translating the results of fundamental biology research on the mechanisms of cell growth and programmed cell death into novel therapies, that are designed to treat the cause of the disease rather than the symptoms. The company has developed a robust and diverse pipeline of self-developed chemical compounds and biopharmaceuticals with the potential to provide new treatment options in dermatology, cardiology and angiology, urology and oncology. CytoTools AG is structured as an investment and holding company and as such holds investments in its subsidiaries DermaTools Biotech GmbH (61%) and CytoPharma GmbH (50%).

### **Contact:**

CytoTools AG

Dr. Mark Andre Freyberg

Klappacher Str. 126

D-64285 Darmstadt

Tel.: +49-6151-95158-12

Fax: +49-6151-95158-13

E-Mail: [freyber@cytotools.de](mailto:freyber@cytotools.de)

UBJ. GmbH

Ingo Janssen

Haus der Wirtschaft

Kapstadtring 10

D-22297 Hamburg

Tel.: +49-40-6378-5410

Fax: +49-40 6378-5423

E-Mail: [ir@ubj.de](mailto:ir@ubj.de)